ArticlePloS one2017
Neuroendocrine carcinoma of the esophagus: Clinicopathological and immunohistochemical features of 14 cases.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Neuroendocrine carcinoma of esophagus: systematic review and meta-analysis of case series.BMC gastroenterology · 2025Pooled it
- Pooled it
- Esophageal Small Cell Carcinoma: From Bench Discoveries to Bedside Therapeutics.International journal of biological sciences · 2026Review
- Unraveling the characteristics of early esophageal neuroendocrine carcinoma using multi-model endoscopy: A retrospective study of serial cases.World journal of gastrointestinal oncology · 2025Article
- Perioperative therapy for limited-stage small cell esophageal carcinoma: a retrospective cohort study.The oncologist · 2025Article
- Gastrointestinal tract, its pathophysiology andWorld journal of gastroenterology · 2025Review
- Long-term survival with multimodal treatment including conversion surgery for locally advanced esophageal neuroendocrine carcinoma: A case report.World journal of gastrointestinal surgery · 2025Article
- Esophageal neuroendocrine carcinoma: A clinical perspective on a rare and challenging disease.Radiology case reports · 2025Article
- Superficial Esophageal Neuroendocrine Carcinoma with Marked Morphological Changes in a Short Period.Internal medicine (Tokyo, Japan) · 2025Article
- Article
- Epidemiology, prognostic factors, and survival analysis in small cell esophageal carcinoma: A population-based study with external validation.Biomolecules & biomedicine · 2025Article
- Gastroesophageal Neuroendocrine Tumors: Outcomes and Management.Journal of clinical medicine · 2025Review
- Epigenetic regulation of p63 blocks squamous-to-neuroendocrine transdifferentiation in esophageal development and malignancy.Science advances · 2024Article
- Article
- Clinical predictors of special type of esophageal cancer.Esophagus : official journal of the Japan Esophageal Society · 2023Review
- MicroRNAs associated with postoperative outcomes in patients with limited stage neuroendocrine carcinoma of the esophagus.Oncology letters · 2023Article
- Late-stage esophageal neuroendocrine carcinoma in a patient treated with tislelizumab combined with anlotinib: a case report.The Journal of international medical research · 2023Article
- High-grade large cell neuroendocrine carcinoma of the esophagus: a case report and review of the literature.Journal of medical case reports · 2023Review
- Article
- Esophagogastric junctional neuroendocrine tumor with adenocarcinoma: A case report.World journal of clinical cases · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuroendocrine carcinoma (NEC) of the esophagus is a rare and highly aggressive disease but the biological features are poorly understood. The objective of this study was to analyze the clinicopathological and immunohistochemical features of NEC of the esophagus.
methodsFourteen patients diagnosed with NEC of the esophagus from 1998 to 2013 were included in this study. Clinicopathologic features, therapeutic outcomes and immunohistochemical results were analyzed.
resultsEleven out of 14 cases showed protruding or localized type with or without ulceration. Only three patients were negative for both lymph node and organ metastasis and seven cases were positive for metastases to distant organs and/or distant lymph nodes. Of the six patients with limited disease (LD), three patients were treated by surgery. Three patients with LD and seven patients with extensive disease (ED) were initially treated with chemotherapy, except for one who underwent concurrent chemo-radiotherapy due to passage disturbance. The median survival of patients with LD was 8.5 months, whereas that of patients with LD was 17 months. Among the 14 cases, 12 cases (83.3%), 13 cases (91.7%) and 12 cases (83.3%) showed positive immunostaining for choromogranin A, synaptophysin and CD56, respectively. Nine of 14 cases (64.2%) presented positive staining for c-kit and most (8/9, 88%) simultaneously showed p53 protein abnormality. Two cases were negative for c-kit and p53, and positive for CK20.
conclusionConsistent with previous reports, the prognosis of NEC of esophagus is dismal. From the results of immunohistochemical study, NEC of esophagus might be divided into two categories due to the staining positivity of c-kit and p53. This study provides new insight into the biology of NEC of the esophagus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.